230.35 +0.03 (0.01%)
Pre-Market: 4:50AM EST
|Bid||228.01 x 800|
|Ask||230.50 x 800|
|Day's Range||226.10 - 230.79|
|52 Week Range||139.64 - 247.64|
|Beta (3Y Monthly)||0.80|
|PE Ratio (TTM)||63.24|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences, Fossil, United Airlines and Boeing highlighted as Zacks Bull and Bear of the Day
Today we'll evaluate Edwards Lifesciences Corporation (NYSE:EW) to determine whether it could have potential as an...
Edwards Lifesciences (EW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Edwards Lifesciences (EW) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Finding top-performing stocks doesn't have to mean a tradeoff with environmental, social and governance values. Microsoft and Edwards Lifesciences are two top stocks that made IBD's just-released ESG 50 list. Their strong fundamentals and ESG initiatives show up in the chart action.